MedTrace Logo

18F-FSPG PET/CT for Cancer Patients on Therapy

NCT02599194 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2019-01-03

Study results available
· View outcomes & findings →

Summary

The goal of this phase 2 study trial is to evaluate the utility of the radiolabel 18F-FSPG used before and after treatment to diagnose, predict, and evaluate response to therapy in patients with a wide variety of metastatic cancers.

Conditions

  • B-Cell Neoplasm
  • Estrogen Receptor Negative
  • HER2/Neu Negative
  • Metastatic Renal Cell Cancer
  • Progesterone Receptor Negative
  • Stage III Mesothelioma
  • Stage III Renal Cell Cancer
  • Stage IIIA Breast Cancer
  • Stage IIIA Non-Small Cell Lung Cancer
  • Stage IIIB Non-Small Cell Lung Cancer
  • Stage IIIC Breast Cancer
  • Stage IV Breast Cancer
  • Stage IV Mesothelioma
  • Stage IV Non-Small Cell Lung Cancer
  • Stage IV Renal Cell Cancer
  • Triple-Negative Breast Carcinoma

Interventions

DRUG

18F-FSPG

Administered intravenously (IV)

DRUG

18F-FDG

Administered intravenously (IV)

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Andrei Iagaru

    lead OTHER

Principal Investigators

  • Andrei M Iagaru, MD · Stanford University

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2016-12-14
Completion
2016-12-14
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02599194 on ClinicalTrials.gov